Real-World Study to Optimize Hepatitis B Tablet Treatment
Part of Digestive system, Infections clinical trials.
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic hepatitis B confirmed by a positive hepatitis B surface antigen (HBsAg) for at least 6 months, or specific liver changes on biopsy within 1 year if HBsAg has been positive for less than 6 months
- You are age 18 to 80
- You can read, understand, and sign informed consent
- You fit one of the study groups based on your blood tests (HBV DNA, ALT), HBeAg status, family history, and/or scan results for liver scarring (TE)
- You must be able to take medicines reliably and follow study instructions (poor compliance is not allowed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study compares two ways of giving treatment for chronic hepatitis B: continuous antiviral therapy versus pulsed treatment. It may help find a schedule that works well and is tolerable for people with hepatitis B.
This study tests whether adding a new medicine (TQA3605) to the usual hepatitis B treatment (nucleoside analogues) can better control the virus in people who still have low levels of the virus despite treatment. It aims to see if the combination is more effective than continuing the standard treatment alone.
This study looks at how well different hepatitis B treatments help lower the risk of liver cancer. It's for people with chronic hepatitis B who are already using or starting certain antiviral or interferon therapies.
This study tests a new combination of medicines to help your immune system control the hepatitis B virus, with the goal of stopping the need for long-term treatment. It may be an option for people who have taken or are currently taking hepatitis B medications.
This study is looking at how well antiviral treatments work to prevent liver cancer in people with chronic hepatitis B who have a family history of the disease. If you are over 30 and taking antiviral medication, you may be able to join.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
Hear when a new Hepatitis B, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.